Now showing items 1-7 of 7

    • Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. 

      Corrie, PG; Marshall, A; Nathan, PD; Lorigan, P; Gore, M; Tahir, S; Faust, G; Kelly, CG; Marples, M; Danson, SJ; Marshall, E; Houston, SJ; Board, RE; Waterston, AM; Nobes, JP; Harries, M; Kumar, S; Goodman, A; Dalgleish, A; Martin-Clavijo, A; Westwell, S; Casasola, R; Chao, D; Maraveyas, A; Patel, PM; Ottensmeier, CH; Farrugia, D; Humphreys, A; Eccles, B; Young, G; Barker, EO; Harman, C; Weiss, M; Myers, KA; Chhabra, A; Rodwell, SH; Dunn, JA; Middleton, MR; AVAST-M Investigators; Nathan, P; Lorigan, P; Dziewulski, P; Holikova, S; Panwar, U; Tahir, S; Faust, G; Thomas, A; Corrie, P; Sirohi, B; Kelly, C; Middleton, M; Marples, M; Danson, S; Lester, J; Marshall, E; Ajaz, M; Houston, S; Board, R; Eaton, D; Waterston, A; Nobes, J; Loo, S; Gray, G; Stubbings, H; Gore, M; Harries, M; Kumar, S; Goodman, A; Dalgleish, A; Martin-Clavijo, A; Marsden, J; Westwell, S; Casasola, R; Chao, D; Maraveyas, A; Marshall, E; Patel, P; Ottensmeier, C; Farrugia, D; Humphreys, A; Eccles, B; Dega, R; Herbert, C; Price, C; Brunt, M; Scott-Brown, M; Hamilton, J; Hayward, RL; Smyth, J; Woodings, P; Nayak, N; Burrows, L; Wolstenholme, V; Wagstaff, J; Nicolson, M; Wilson, A; Barlow, C; Scrase, C; Podd, T; Gonzalez, M; Stewart, J; Highley, M; Wolstenholme, V; Grumett, S; Goodman, A; Talbot, T; Nathan, K; Coltart, R; Gee, B; Gore, M; Farrugia, D; Martin-Clavijo, A; Marsden, J; Price, C; Farrugia, D; Nathan, K; Coltart, R; Nathan, K; Coltart, R (2018-08)
      Background Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma ...
    • Best practice in active surveillance for men with prostate cancer: a Prostate Cancer UK consensus statement. 

      Merriel, SWD; Hetherington, L; Seggie, A; Castle, JT; Cross, W; Roobol, MJ; Gnanapragasam, V; Moore, CM; Prostate Cancer UK Expert Reference Group on Active Surveillance (2019-07)
      OBJECTIVES:To develop a consensus statement on current best practice of active surveillance (AS) in the UK, informed by patients and clinical experts. SUBJECTS AND METHODS:A consensus statement was drafted on the basis of ...
    • Low-risk Prostate Cancer: Identification, Management, and Outcomes. 

      Moschini, M; Carroll, PR; Eggener, SE; Epstein, JI; Graefen, M; Montironi, R; Parker, C (2017-08)
      Context The incidence of low-risk prostate cancer (PCa) has increased as a consequence of prostate-specific antigen testing.Objective In this collaborative review article, we examine recent literature regarding low-risk ...
    • Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort. 

      Henderson, DR; de Souza, NM; Thomas, K; Riches, SF; Morgan, VA; Sohaib, SA; Dearnaley, DP; Parker, CC; van As, NJ (2016-06)
      In active surveillance (AS) for prostate cancer there are few data on long-term outcomes associated with novel imaging markers.To determine long-term outcomes with respect to the apparent diffusion coefficient (ADC) derived ...
    • Positron Emission Tomography/Computed Tomography with <sup>89</sup>Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. 

      Hekman, MCH; Rijpkema, M; Aarntzen, EH; Mulder, SF; Langenhuijsen, JF; Oosterwijk, E; Boerman, OC; Oyen, WJG; Mulders, PFA (2018-09)
      Based on the high expression of carbonic anhydrase IX (CAIX) in 95% of clear cell renal cell carcinoma (ccRCC), the anti-CAIX monoclonal antibody girentuximab can be used for the detection of ccRCC. This clinical study ...
    • The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. 

      van de Donk, NWCJ; Palumbo, A; Johnsen, HE; Engelhardt, M; Gay, F; Gregersen, H; Hajek, R; Kleber, M; Ludwig, H; Morgan, G; Musto, P; Plesner, T; Sezer, O; Terpos, E; Waage, A; Zweegman, S; Einsele, H; Sonneveld, P; Lokhorst, HM; European Myeloma Network (2014-06)
      Monoclonal gammopathy of undetermined significance is one of the most common pre-malignant disorders. IgG and IgA monoclonal gammopathy of undetermined significance are precursor conditions of multiple myeloma; light-chain ...
    • When no treatment is the best treatment: Active surveillance strategies for low risk prostate cancers. 

      Stavrinides, V; Parker, CC; Moore, CM (2017-07)
      Although the incidence of prostate cancer is rising due to PSA screening and increased life expectancy, the metastatic potential of low-grade, organ-confined disease remains low. An increasing number of studies suggest ...